Clinical Trials Browser

INDUSTRY × cediranib × Thoracic × Clear all

NCT03334617 2025-10-27

HUDSON

Phase 2 Active not recruiting

528 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT00243347 2013-10-17

The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer

Phase 1 Completed

19 enrolled 7 charts

Head & NeckThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms

NCT00621361 2012-12-17

Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients

Phase 1 Completed

Lung Neoplasms

NCT00539331 2011-06-01

Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT00475956 2010-04-15

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

Phase 1 Completed

BreastGastrointestinalGynecologicPlasma cellThoracic

Breast Neoplasms, Choriocarcinoma, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Neoplasms, Plasma Cell